Drug Profile
MK 8189
Alternative Names: MK-8189Latest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antidementias; Antipsychotics
- Mechanism of Action Phosphodiesterase 10A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Schizophrenia
- Phase I Alzheimer's disease
Most Recent Events
- 23 Feb 2024 Merck Sharp & Dohme plans a phase I trial for Bipolar I disorder in March 2024 (NCT06273774)
- 22 Feb 2024 Merck Sharp & Dohme LLC completes a phase I trial in Schizophrenia in the US (PO) (NCT05893862)
- 26 Jun 2023 Merck Sharp & Dohme initiates a phase I MK-8189-01 (TQT) trial for Schizophrenia in USA (PO) (NCT05893862)